

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Investor News

Live webcast of NeuroSearch's presentation to be held Monday 7 January at the JPMorgan Healthcare Conference in San Francisco

NeuroSearch will make a presentation at the upcoming 26th Annual JPMorgan Healthcare Conference from 7 – 10 January 2008 in San Francisco, USA.

NeuroSearch's presentation is scheduled for

Monday, 7 January 2008 at 2:30 pm (local time)

and will be held by CEO Flemming Pedersen.

The presentation will be live webcast and can be accessed on www.metameetings.com/webcasts/jpmorgan/healthcare08. Viewers are encouraged to log on to the website approximately five minutes prior to the presentation to register and download any software. After registration, the conference welcome page will appear: click on "Webcast Agenda", choose "Monday, January 7" and then "NeuroSearch".

A link to the JPMorgan webcast will also be accessible from NeuroSearch's website www.neurosearch.com prior to the presentation at the conference.

The webcast will be available on demand approximately 24 hours after the live presentation and will be archived for three months.

Contact person:

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 13 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy/pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.